nafamostat has been researched along with Acute Edematous Pancreatitis in 64 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of nafamostat mesilate in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) by conduct a systematic review and meta-analysis." | 9.41 | Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis based on prospective, randomized, and controlled trials. ( Cheng, Z; Deng, C; Deng, M; Xie, Y; Zhang, H, 2023) |
| "Continuous regional arterial infusion (CRAI) of protease inhibitor nafamostat mesilate (NM) is used in the context of predicted severe acute pancreatitis (SAP) to prevent the development of pancreatic necrosis." | 9.34 | Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial. ( Gabata, T; Haradome, H; Hirota, M; Ikeda, K; Isaji, S; Ishida, E; Ito, T; Iwasaki, E; Kataoka, K; Kayaba, C; Kimura, K; Kitamura, K; Kozaka, K; Maguchi, H; Masamune, A; Mayumi, T; Mitoro, A; Miura, S; Nakai, Y; Nakamura, R; Sanuki, T; Sawano, H; Shimosegawa, T; Takeda, K; Takenaka, M; Takeyama, Y; Yamagiwa, K, 2020) |
| "Although prolonged intravenous infusion (24 hours) of nafamostat mesilate is effective for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis, it requires hospitalization and is expensive." | 9.22 | A Randomized Comparative Study of 24- and 6-Hour Infusion of Nafamostat Mesilate for the Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Prospective Randomized Comparison Trial. ( Choi, CW; Kang, DH; Kim, HW; Kim, SJ; Nam, HS; Park, SB; Song, BJ, 2016) |
| "The objective of this study was to investigate whether prophylactic administration of nafamostat mesilate reduces the incidence of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP), its efficacy, and risk factors for PEP." | 9.20 | Randomized controlled trial for efficacy of nafamostat mesilate in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis. ( Chijiiwa, K; Hiyoshi, M; Imamura, N; Nagano, M; Ohuchida, J, 2015) |
| "Infusion of the protease inhibitor nafamostat mesilate (20 mg) effectively prevents post-ERCP pancreatitis, but only in low-risk groups." | 9.15 | Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients? ( Cho, M; Choi, CW; Chung, CW; Kang, DH; Kim, DU; Kim, HW; Park, KT; Park, SB; Yoon, KT, 2011) |
| "Prophylactic intravenous nafamostat mesilate reduces the frequency of post-ERCP pancreatitis." | 9.15 | Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized, double-blind, controlled trial. ( Hahn, T; Huh, KR; Kim, JH; Kim, KO; Kim, YJ; Kwon, YJ; Lehman, GA; Park, CH; Park, CK; Park, SH; Yoo, KS, 2011) |
| "To determine whether nafamostat mesylate prophylaxis decreases the incidence of post-ERCP pancreatitis (PEP)." | 9.14 | Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis. ( Cho, M; Choi, CW; Eum, JS; Kang, DH; Kim, DU; Kim, GH; Kim, ID; Lee, SM; Song, GA, 2009) |
| "We aimed to evaluate the efficacy of nafamostat on the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP)." | 8.91 | Nafamostat mesilate for prevention of post-ERCP pancreatitis: a meta-analysis of prospective, randomized, controlled trials. ( Hu, G; Li, S; Wan, R; Wang, X; Yu, G, 2015) |
| "Nafamostat mesilate decreases the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP)." | 8.12 | The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis. ( Cho, IR; Choi, JH; Chun, JW; Huh, G; Kim, JS; Kim, YT; Lee, SH; Paik, WH; Park, N; Ryu, JK, 2022) |
| "The development of pancreatitis was prevented by treating mice with nafamostat mesilate before induction, however, this finding was not observed if administered after injection of cerulein." | 7.74 | Effects of nafamostat mesilate on the prevention of cerulein-induced acute pancreatitis. ( Jung, HC; Kim, YT; Lee, JK; Lee, SH; Park, JK; Ryu, JK; Yoon, WJ; Yoon, YB, 2008) |
| "Long-term effects of nafamostat mesylate, a protease inhibitor, and imipenem, an antibiotic, on trypsintaurocholate-induced acute pancreatitis were studied in rats." | 7.70 | Long-term effects of nafamostat and imipenem on experimental acute pancreatitis in rats. ( Hayakawa, T; Ishiguro, H; Kitagawa, M; Naruse, S; Ozaki, T; Seki, Y; Wang, Y, 2000) |
| " infusion performed 1 h after intrabiliary injection of enterokinase/sodium taurocholate to induce acute pancreatitis (AP): (1) Saline; (2) 5 micrograms/kg/h nafamostat mesilate (FUT-175); (3) 10 micrograms/kg/h FUT-175; and (4) 25 micrograms/kg/h FUT-175." | 7.69 | Nafamostat mesilate on the course of acute pancreatitis. Protective effect on peritoneal permeability and relation with supervening pulmonary distress. ( Chui, DH; Fesce, E; Idéo, G; Marotta, F; Rezakovic, I; Suzuki, K, 1994) |
| "This study was undertaken to determine whether synthetic proteinase inhibitors--nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) have any influence on multiorgan oxidant-antioxidant balance in acute haemorrhagic pancreatitis induced in Wistar rats using a retrograde intraductal injection of 5% Na-taurocholate." | 7.69 | The effect of nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) on multiorgan oxidant-antioxidant balance in acute experimental pancreatitis. ( Dabrowski, A; Gabryelewicz, A, 1994) |
| "Trypsinogen activation peptide (TAP) concentration and alpha 2-macroglobulin-trypsin complex (alpha 2M-T) activity were measured in two experimental models of acute pancreatitis in rats to evaluate the significance of activation of trypsinogen in acute pancreatitis." | 7.69 | Activation of trypsinogen in experimental models of acute pancreatitis in rats. ( Hayakawa, T; Hirao, S; Kitagawa, M; Nakae, Y; Naruse, S; Yamamoto, R, 1995) |
| "The aim of this study was to investigate the effect of Nafamostat mesilate (FUT-175) on some blood platelet properties during the first hours of acute experimental pancreatitis (AEP) in dogs." | 7.68 | Blood platelet function in canine acute pancreatitis with reference to treatment with Nafamostat mesilate (FUT-175). ( Bielawiec, M; Bodzenta-Lukaszyk, A; Gabryelewicz, A; Lukaszyk, A, 1992) |
| "This in vivo and in vitro study demonstrates the protective effects of a new synthetic protease inhibitor--nafamostat mesilate, FUT-175--on increased cellular and lysosomal fragility within acinar cells during the early stage of cerulein-induced acute pancreatitis in rats." | 7.68 | Protective effect of nafamostat mesilate on cellular and lysosomal fragility of acinar cells in rat cerulein pancreatitis. ( Ando, K; Hirano, T; Imanishi, K; Manabe, T; Tobe, T; Yotsumoto, F, 1992) |
| "FUT has been reported as a drug for the treatments of DIC (disseminated intravascular coagulation) and acute pancreatitis and as an anticoagulant in extracorporeal circulation." | 6.41 | [Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation]. ( Tsukagoshi, S, 2000) |
| "To evaluate the efficacy of nafamostat mesilate in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) by conduct a systematic review and meta-analysis." | 5.41 | Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis based on prospective, randomized, and controlled trials. ( Cheng, Z; Deng, C; Deng, M; Xie, Y; Zhang, H, 2023) |
| "Mizoribine has been recognized to have an acceptable toxicity profile compared with other immunosuppressants." | 5.35 | A sudden onset of diabetic ketoacidosis and acute pancreatitis after introduction of mizoribine therapy in a patient with rheumatoid arthritis. ( Ebihara, K; Mori, S, 2008) |
| "Continuous regional arterial infusion (CRAI) of protease inhibitor nafamostat mesilate (NM) is used in the context of predicted severe acute pancreatitis (SAP) to prevent the development of pancreatic necrosis." | 5.34 | Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial. ( Gabata, T; Haradome, H; Hirota, M; Ikeda, K; Isaji, S; Ishida, E; Ito, T; Iwasaki, E; Kataoka, K; Kayaba, C; Kimura, K; Kitamura, K; Kozaka, K; Maguchi, H; Masamune, A; Mayumi, T; Mitoro, A; Miura, S; Nakai, Y; Nakamura, R; Sanuki, T; Sawano, H; Shimosegawa, T; Takeda, K; Takenaka, M; Takeyama, Y; Yamagiwa, K, 2020) |
| "Acute pancreatitis was induced in 13 anesthetized dogs by retrograde injection of bile mixed with trypsin into the pancreatic duct." | 5.28 | Beneficial effect of therapeutic infusion of nafamostat mesilate (FUT-175) on hemodynamics in experimental acute pancreatitis. ( Babicki, A; Basinski, A; Dobosz, M; Juszkiewicz, P; Sledzinski, Z; Stanek, A; Wajda, Z, 1991) |
| " Nafamostat mesylate (nafamostat) is a drug licensed in Japan and Korea for indications including acute pancreatitis and disseminated intravascular coagulation." | 5.22 | Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review. ( Bowen, AC; Denholm, JT; Dore, GJ; Hernández-Mitre, MP; Hills, TE; Lewin, SR; McQuilten, Z; Morpeth, SC; Paterson, DL; Roberts, JA; Tong, SYC; Venkatesh, B, 2022) |
| "Although prolonged intravenous infusion (24 hours) of nafamostat mesilate is effective for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis, it requires hospitalization and is expensive." | 5.22 | A Randomized Comparative Study of 24- and 6-Hour Infusion of Nafamostat Mesilate for the Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Prospective Randomized Comparison Trial. ( Choi, CW; Kang, DH; Kim, HW; Kim, SJ; Nam, HS; Park, SB; Song, BJ, 2016) |
| "The objective of this study was to investigate whether prophylactic administration of nafamostat mesilate reduces the incidence of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP), its efficacy, and risk factors for PEP." | 5.20 | Randomized controlled trial for efficacy of nafamostat mesilate in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis. ( Chijiiwa, K; Hiyoshi, M; Imamura, N; Nagano, M; Ohuchida, J, 2015) |
| "Prophylactic intravenous nafamostat mesilate reduces the frequency of post-ERCP pancreatitis." | 5.15 | Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized, double-blind, controlled trial. ( Hahn, T; Huh, KR; Kim, JH; Kim, KO; Kim, YJ; Kwon, YJ; Lehman, GA; Park, CH; Park, CK; Park, SH; Yoo, KS, 2011) |
| "Infusion of the protease inhibitor nafamostat mesilate (20 mg) effectively prevents post-ERCP pancreatitis, but only in low-risk groups." | 5.15 | Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients? ( Cho, M; Choi, CW; Chung, CW; Kang, DH; Kim, DU; Kim, HW; Park, KT; Park, SB; Yoon, KT, 2011) |
| "To determine whether nafamostat mesylate prophylaxis decreases the incidence of post-ERCP pancreatitis (PEP)." | 5.14 | Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis. ( Cho, M; Choi, CW; Eum, JS; Kang, DH; Kim, DU; Kim, GH; Kim, ID; Lee, SM; Song, GA, 2009) |
| "CRAI of nafamostat and imipenem in acute necrotizing pancreatitis was effective in reducing mortality and preventing the development of pancreatic infection." | 5.08 | Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. ( Kakugawa, Y; Matsuno, S; Sunamura, M; Takeda, K, 1996) |
| "We aimed to evaluate the efficacy of nafamostat on the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP)." | 4.91 | Nafamostat mesilate for prevention of post-ERCP pancreatitis: a meta-analysis of prospective, randomized, controlled trials. ( Hu, G; Li, S; Wan, R; Wang, X; Yu, G, 2015) |
| "The proteolytic enzyme inhibitor nafamostat mesylate is widely used for the treatment of acute pancreatitis and disseminated intravascular coagulation." | 4.31 | Identification of Risk Factors for Phlebitis in Patients Treated with Nafamostat Mesylate. ( Kawakami, Y; Kotake, K; Tahira, A, 2023) |
| "Nafamostat mesilate (NM), a synthetic broad-spectrum serine protease inhibitor, has been commonly used for treating acute pancreatitis (AP) and other inflammatory-associated diseases in some East Asia countries." | 4.31 | Nafamostat mesilate prevented caerulein-induced pancreatic injury by targeting HDAC6-mediated NLRP3 inflammasome activation. ( Chen, P; He, WQ; Huang, L; Liu, Y; Ren, JD; Tang, YR; Zhao, LJ, 2023) |
| "Nafamostat mesilate decreases the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP)." | 4.12 | The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis. ( Cho, IR; Choi, JH; Chun, JW; Huh, G; Kim, JS; Kim, YT; Lee, SH; Paik, WH; Park, N; Ryu, JK, 2022) |
| "The established referred allodynia/hyperalgesia following cerulein treatment was abolished by post-treatment with nafamostat mesilate, a proteinase inhibitor, and with capsazepine, a TRPV1 antagonist, in mice." | 3.76 | The proteinase/proteinase-activated receptor-2/transient receptor potential vanilloid-1 cascade impacts pancreatic pain in mice. ( Akashi, R; Ishikura, H; Kawabata, A; Kitamura, T; Matsumura, K; Matsunami, M; Naruse, M; Nishimura, S; Sekiguchi, F; Shinozaki, Y, 2010) |
| "The development of pancreatitis was prevented by treating mice with nafamostat mesilate before induction, however, this finding was not observed if administered after injection of cerulein." | 3.74 | Effects of nafamostat mesilate on the prevention of cerulein-induced acute pancreatitis. ( Jung, HC; Kim, YT; Lee, JK; Lee, SH; Park, JK; Ryu, JK; Yoon, WJ; Yoon, YB, 2008) |
| "We treated five patients with severe acute pancreatitis by continuous arterial infusion (CAI) of protease inhibitor, nafamostat mesilate." | 3.70 | [Continuous arterial infusion of protease inhibitor with supplementary therapy for the patients with severe acute pancreatitis--clinical effect of arterial injection of ulinastatin]. ( Fukui, K; Hara, A; Ichikawa, M; Ito, T; Matsukawa, H; Okuda, S; Sato, K; Seki, H; Shiraga, N; Takizawa, K; Yamataka, K; Yoshioka, M, 1998) |
| "Long-term effects of nafamostat mesylate, a protease inhibitor, and imipenem, an antibiotic, on trypsintaurocholate-induced acute pancreatitis were studied in rats." | 3.70 | Long-term effects of nafamostat and imipenem on experimental acute pancreatitis in rats. ( Hayakawa, T; Ishiguro, H; Kitagawa, M; Naruse, S; Ozaki, T; Seki, Y; Wang, Y, 2000) |
| " infusion performed 1 h after intrabiliary injection of enterokinase/sodium taurocholate to induce acute pancreatitis (AP): (1) Saline; (2) 5 micrograms/kg/h nafamostat mesilate (FUT-175); (3) 10 micrograms/kg/h FUT-175; and (4) 25 micrograms/kg/h FUT-175." | 3.69 | Nafamostat mesilate on the course of acute pancreatitis. Protective effect on peritoneal permeability and relation with supervening pulmonary distress. ( Chui, DH; Fesce, E; Idéo, G; Marotta, F; Rezakovic, I; Suzuki, K, 1994) |
| "Trypsinogen activation peptide (TAP) concentration and alpha 2-macroglobulin-trypsin complex (alpha 2M-T) activity were measured in two experimental models of acute pancreatitis in rats to evaluate the significance of activation of trypsinogen in acute pancreatitis." | 3.69 | Activation of trypsinogen in experimental models of acute pancreatitis in rats. ( Hayakawa, T; Hirao, S; Kitagawa, M; Nakae, Y; Naruse, S; Yamamoto, R, 1995) |
| "This study was undertaken to determine whether synthetic proteinase inhibitors--nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) have any influence on multiorgan oxidant-antioxidant balance in acute haemorrhagic pancreatitis induced in Wistar rats using a retrograde intraductal injection of 5% Na-taurocholate." | 3.69 | The effect of nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) on multiorgan oxidant-antioxidant balance in acute experimental pancreatitis. ( Dabrowski, A; Gabryelewicz, A, 1994) |
| "This in vivo and in vitro study demonstrates the protective effects of a new synthetic protease inhibitor--nafamostat mesilate, FUT-175--on increased cellular and lysosomal fragility within acinar cells during the early stage of cerulein-induced acute pancreatitis in rats." | 3.68 | Protective effect of nafamostat mesilate on cellular and lysosomal fragility of acinar cells in rat cerulein pancreatitis. ( Ando, K; Hirano, T; Imanishi, K; Manabe, T; Tobe, T; Yotsumoto, F, 1992) |
| "The effect of FUT-175, a new synthetic trypsin inhibitor, was evaluated in a lethal model of acute hemorrhagic pancreatitis induced by feeding mice a choline-deficient, ethionine-supplemented diet (CDE diet)." | 3.68 | Effect of protease inhibitor FUT-175 on acute hemorrhagic pancreatitis in mice. ( Frey, CF; Isaji, S; Ruebner, B; Stanten, R; Suzuki, M, 1992) |
| "The aim of this study was to investigate the effect of Nafamostat mesilate (FUT-175) on some blood platelet properties during the first hours of acute experimental pancreatitis (AEP) in dogs." | 3.68 | Blood platelet function in canine acute pancreatitis with reference to treatment with Nafamostat mesilate (FUT-175). ( Bielawiec, M; Bodzenta-Lukaszyk, A; Gabryelewicz, A; Lukaszyk, A, 1992) |
| "To confirm that trypsin activity is a most important initiating factor in closed duodenal loop pancreatitis in rats, we observed the course of acute pancreatitis when trypsinogen activation was inhibited by intraduodenal infusion of a potent synthetic trypsin inhibitor (TI, nafamostat mesilate) but the other conditions were left unchanged." | 3.68 | Prevention of experimental acute pancreatitis by intraduodenal trypsin inhibitor in rat. ( Hayakawa, T; Kiriyama, S; Kitagawa, M; Kondo, T; Ono, H; Sakai, Y; Shibata, T; Sobajima, H, 1990) |
| "FUT has been reported as a drug for the treatments of DIC (disseminated intravascular coagulation) and acute pancreatitis and as an anticoagulant in extracorporeal circulation." | 2.41 | [Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation]. ( Tsukagoshi, S, 2000) |
| "The Japanese severity score (JSS) for acute pancreatitis was revised in 2008." | 1.35 | Utility of the new Japanese severity score and indications for special therapies in acute pancreatitis. ( Kamei, K; Ku, Y; Kuroda, Y; Ohyanagi, H; Satoi, S; Sawa, H; Shinzeki, M; Takeyama, Y; Ueda, T; Yasuda, T, 2009) |
| "Mizoribine has been recognized to have an acceptable toxicity profile compared with other immunosuppressants." | 1.35 | A sudden onset of diabetic ketoacidosis and acute pancreatitis after introduction of mizoribine therapy in a patient with rheumatoid arthritis. ( Ebihara, K; Mori, S, 2008) |
| "After the induction of severe acute pancreatitis, rats received intravenous or regional intraarterial infusion of nafamostat and then concentrations of trypsinogen activated peptide (TAP) and serum interleukin (IL-6), and histologic sections of the pancreas were examined and the 96-hour survival rate was evaluated." | 1.33 | Rat experimental model of continuous regional arterial infusion of protease inhibitor and its effects on severe acute pancreatitis. ( Egawa, S; Fukuyama, S; Matsuda, K; Matsuno, S; Mikami, Y; Qiu-Feng, H; Sunamura, M; Takeda, K, 2005) |
| "30% at 24 hours), and bacterial infection of the peritoneal fluid, mesenteric lymph nodes, and pancreas was completely prevented in group III." | 1.31 | Therapeutic efficacy of continuous arterial infusion of an antibiotic and a protease inhibitor via the superior mesenteric artery for acute pancreatitis in an animal model. ( Isaji, S; Takagi, K, 2000) |
| "Acute pancreatitis was induced in 19 anesthetized dogs by retrograde injection of bile mixed with trypsin into the pancreatic duct." | 1.28 | Synthetic antiproteases in acute pancreatitis: an experimental study. ( Babicki, A; Basiński, A; Dobosz, M; Juszkiewicz, P; Sledziński, Z; Wajda, Z, 1992) |
| "Acute pancreatitis was induced in 13 anesthetized dogs by retrograde injection of bile mixed with trypsin into the pancreatic duct." | 1.28 | Beneficial effect of therapeutic infusion of nafamostat mesilate (FUT-175) on hemodynamics in experimental acute pancreatitis. ( Babicki, A; Basinski, A; Dobosz, M; Juszkiewicz, P; Sledzinski, Z; Stanek, A; Wajda, Z, 1991) |
| "The coagulo-fibrinolytic changes after acute pancreatitis was induced by the intraductal injection of an autologous bile and trypsin mixture showed decreased platelet counts, decreased plasma fibrinogen levels, prolonged partial prothrombin time and increased fibrinogen degradation products." | 1.28 | Effect of a synthetic protease inhibitor (Fut-175) on coagulation abnormalities during experimental acute pancreatitis in dogs. ( Ha, S; Haku, A; Hiura, A; Nishiwaki, H; Satake, K; Umeyama, K, 1990) |
| " When a new synthetic antiprotease (nafamstat mesilate) in a dosage of 0." | 1.27 | Toxic products in hemorrhagic ascitic fluid generated during experimental acute hemorrhagic pancreatitis in dogs and a treatment which reduces their effect. ( Koh, I; Nishiwaki, H; Satake, K; Umeyama, K, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (10.94) | 18.7374 |
| 1990's | 23 (35.94) | 18.2507 |
| 2000's | 14 (21.88) | 29.6817 |
| 2010's | 12 (18.75) | 24.3611 |
| 2020's | 8 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kodama, K | 1 |
| Imai, T | 1 |
| Asai, Y | 1 |
| Kozu, Y | 1 |
| Hayashi, K | 1 |
| Shimizu, T | 1 |
| Gon, Y | 1 |
| Ootsuka, S | 1 |
| Kim, JS | 1 |
| Lee, SH | 2 |
| Park, N | 1 |
| Huh, G | 1 |
| Chun, JW | 1 |
| Choi, JH | 1 |
| Cho, IR | 1 |
| Paik, WH | 1 |
| Ryu, JK | 2 |
| Kim, YT | 2 |
| Hernández-Mitre, MP | 1 |
| Tong, SYC | 1 |
| Denholm, JT | 1 |
| Dore, GJ | 1 |
| Bowen, AC | 1 |
| Lewin, SR | 1 |
| Venkatesh, B | 1 |
| Hills, TE | 1 |
| McQuilten, Z | 1 |
| Paterson, DL | 1 |
| Morpeth, SC | 1 |
| Roberts, JA | 1 |
| Kotake, K | 1 |
| Tahira, A | 1 |
| Kawakami, Y | 1 |
| Chen, P | 1 |
| Zhao, LJ | 1 |
| Huang, L | 1 |
| He, WQ | 1 |
| Tang, YR | 1 |
| Liu, Y | 1 |
| Ren, JD | 1 |
| Xie, Y | 1 |
| Cheng, Z | 1 |
| Deng, C | 1 |
| Deng, M | 1 |
| Zhang, H | 1 |
| Hirota, M | 2 |
| Shimosegawa, T | 2 |
| Kitamura, K | 2 |
| Takeda, K | 7 |
| Takeyama, Y | 2 |
| Mayumi, T | 1 |
| Ito, T | 3 |
| Takenaka, M | 1 |
| Iwasaki, E | 1 |
| Sawano, H | 1 |
| Ishida, E | 1 |
| Miura, S | 1 |
| Masamune, A | 1 |
| Nakai, Y | 1 |
| Mitoro, A | 1 |
| Maguchi, H | 1 |
| Kimura, K | 1 |
| Sanuki, T | 1 |
| Haradome, H | 1 |
| Kozaka, K | 1 |
| Gabata, T | 1 |
| Kataoka, K | 2 |
| Isaji, S | 3 |
| Nakamura, R | 1 |
| Yamagiwa, K | 1 |
| Kayaba, C | 1 |
| Ikeda, K | 1 |
| Matsumoto, T | 1 |
| Okuwaki, K | 1 |
| Imaizumi, H | 3 |
| Kida, M | 3 |
| Iwai, T | 1 |
| Yamauchi, H | 1 |
| Kaneko, T | 1 |
| Hasegawa, R | 1 |
| Masutani, H | 1 |
| Tadehara, M | 1 |
| Adachi, K | 1 |
| Watanabe, M | 1 |
| Kurosu, T | 1 |
| Tamaki, A | 1 |
| Kikuchi, H | 1 |
| Ohno, T | 1 |
| Koizumi, W | 2 |
| Yuhara, H | 1 |
| Ogawa, M | 1 |
| Kawaguchi, Y | 1 |
| Igarashi, M | 1 |
| Mine, T | 1 |
| Ohuchida, J | 1 |
| Chijiiwa, K | 1 |
| Imamura, N | 1 |
| Nagano, M | 1 |
| Hiyoshi, M | 1 |
| Yu, G | 1 |
| Li, S | 1 |
| Wan, R | 1 |
| Wang, X | 1 |
| Hu, G | 1 |
| Goto, S | 1 |
| Ookawara, S | 1 |
| Tabei, K | 1 |
| Kim, SJ | 1 |
| Kang, DH | 3 |
| Kim, HW | 2 |
| Choi, CW | 3 |
| Park, SB | 2 |
| Song, BJ | 1 |
| Nam, HS | 1 |
| Mori, S | 1 |
| Ebihara, K | 1 |
| Ueda, T | 1 |
| Yasuda, T | 1 |
| Kamei, K | 1 |
| Satoi, S | 1 |
| Sawa, H | 1 |
| Shinzeki, M | 1 |
| Ku, Y | 1 |
| Kuroda, Y | 1 |
| Ohyanagi, H | 1 |
| Kurisu, S | 1 |
| Inoue, I | 1 |
| Kawagoe, T | 1 |
| Kim, GH | 1 |
| Eum, JS | 1 |
| Lee, SM | 1 |
| Song, GA | 1 |
| Kim, DU | 2 |
| Kim, ID | 1 |
| Cho, M | 2 |
| Piaścik, M | 1 |
| Rydzewska, G | 2 |
| Milewski, J | 1 |
| Olszewski, S | 1 |
| Furmanek, M | 1 |
| Walecki, J | 1 |
| Gabryelewicz, A | 4 |
| Nishimura, S | 1 |
| Ishikura, H | 1 |
| Matsunami, M | 1 |
| Shinozaki, Y | 1 |
| Sekiguchi, F | 1 |
| Naruse, M | 1 |
| Kitamura, T | 1 |
| Akashi, R | 1 |
| Matsumura, K | 1 |
| Kawabata, A | 1 |
| Yoo, KS | 1 |
| Huh, KR | 1 |
| Kim, YJ | 1 |
| Kim, KO | 1 |
| Park, CH | 1 |
| Hahn, T | 1 |
| Park, SH | 1 |
| Kim, JH | 1 |
| Park, CK | 1 |
| Kwon, YJ | 1 |
| Lehman, GA | 1 |
| Park, KT | 1 |
| Chung, CW | 1 |
| Yoon, KT | 1 |
| Kwon, YH | 1 |
| Kim, JY | 1 |
| Lee, SJ | 1 |
| Jang, SY | 1 |
| Park, HW | 1 |
| Yang, HM | 1 |
| Jung, MK | 1 |
| Jeon, SW | 1 |
| Cho, CM | 1 |
| Tak, WY | 1 |
| Kweon, YO | 1 |
| Kim, SK | 1 |
| Okada, T | 1 |
| Honda, S | 1 |
| Miyagi, H | 1 |
| Minato, M | 1 |
| Kubota, KC | 1 |
| Taketomi, A | 1 |
| Hamada, Y | 1 |
| Miyazawa, S | 1 |
| Souma, K | 1 |
| Sunakawa, K | 1 |
| Kuroyama, M | 1 |
| Imamura, T | 1 |
| Yoshida, H | 1 |
| Ishikawa, A | 1 |
| Katayose, K | 1 |
| Nozu, F | 1 |
| Ikegami, A | 1 |
| Takahashi, A | 1 |
| Niikawa, J | 1 |
| Tanaka, S | 1 |
| Ishii, H | 1 |
| Hoshino, M | 1 |
| Kusano, M | 1 |
| Matsui, S | 1 |
| Hashimoto, T | 1 |
| Mitamura, K | 1 |
| Nishimaki, H | 1 |
| Okuno, J | 1 |
| Kataoka, Y | 1 |
| Kida, Y | 1 |
| Soma, K | 1 |
| Saigenji, K | 1 |
| Kohsaki, T | 1 |
| Nishimori, I | 1 |
| Onishi, S | 1 |
| Mikami, Y | 1 |
| Matsuda, K | 1 |
| Qiu-Feng, H | 1 |
| Fukuyama, S | 1 |
| Egawa, S | 1 |
| Sunamura, M | 3 |
| Matsuno, S | 5 |
| Lee, JK | 1 |
| Park, JK | 1 |
| Yoon, WJ | 1 |
| Jung, HC | 1 |
| Yoon, YB | 1 |
| Iwaki, M | 2 |
| Ozeki, M | 2 |
| Sato, T | 2 |
| Suzuki, K | 2 |
| Motoyoshi, A | 2 |
| Suzuki, S | 1 |
| Fujita, M | 1 |
| Aoyama, T | 2 |
| Araida, T | 1 |
| Frey, CF | 2 |
| Ruebner, B | 2 |
| Carlson, J | 1 |
| King, J | 1 |
| Marotta, F | 1 |
| Fesce, E | 1 |
| Rezakovic, I | 1 |
| Chui, DH | 1 |
| Idéo, G | 1 |
| Nakae, Y | 1 |
| Naruse, S | 2 |
| Kitagawa, M | 3 |
| Hirao, S | 1 |
| Yamamoto, R | 1 |
| Hayakawa, T | 3 |
| Dabrowski, A | 1 |
| Kitagawa, H | 1 |
| Chang, H | 1 |
| Fujita, T | 1 |
| Kakugawa, Y | 4 |
| Kawasaki, K | 1 |
| Arimura, Y | 1 |
| Hirata, H | 1 |
| Suzuki, T | 1 |
| Kakumoto, Y | 1 |
| Kaneto, H | 1 |
| Mihara, M | 1 |
| Imai, K | 1 |
| Miyasaka, Y | 1 |
| Ono, K | 1 |
| Nagayama, K | 1 |
| Murakami, T | 1 |
| Noguchi, O | 1 |
| Uchihara, M | 1 |
| Izumi, N | 1 |
| Miyake, S | 1 |
| Kubota, K | 1 |
| Enomoto, N | 1 |
| Tanaka, Y | 1 |
| Marumo, F | 1 |
| Sato, C | 1 |
| Matsukawa, H | 1 |
| Hara, A | 1 |
| Fukui, K | 1 |
| Sato, K | 1 |
| Ichikawa, M | 1 |
| Yoshioka, M | 1 |
| Seki, H | 1 |
| Yamataka, K | 1 |
| Takizawa, K | 1 |
| Okuda, S | 1 |
| Shiraga, N | 1 |
| Hongo, H | 1 |
| Takano, H | 1 |
| Imai, A | 1 |
| Yamaguchi, T | 1 |
| Boku, Y | 1 |
| Fujii, T | 1 |
| Naito, Y | 1 |
| Yoshida, N | 1 |
| Yoshikawa, T | 1 |
| Kondo, M | 1 |
| Tsukagoshi, S | 1 |
| Takagi, K | 1 |
| Wang, Y | 1 |
| Ishiguro, H | 1 |
| Seki, Y | 1 |
| Ozaki, T | 1 |
| Kirschfink, M | 1 |
| Manabe, T | 2 |
| Hirano, T | 2 |
| Imanishi, K | 1 |
| Ando, K | 1 |
| Yotsumoto, F | 1 |
| Tobe, T | 2 |
| Kashima, K | 1 |
| Umehara, K | 1 |
| Suzuki, M | 1 |
| Stanten, R | 1 |
| Kimura, W | 1 |
| Meyer, F | 1 |
| Hess, D | 1 |
| Kirchner, T | 1 |
| Fischbach, W | 1 |
| Mössner, J | 1 |
| Lukaszyk, A | 1 |
| Bodzenta-Lukaszyk, A | 1 |
| Bielawiec, M | 1 |
| Murakawa, M | 1 |
| Okamura, T | 1 |
| Shibuya, T | 1 |
| Harada, M | 1 |
| Otsuka, T | 1 |
| Niho, Y | 1 |
| Yoshida, K | 1 |
| Toki, F | 1 |
| Takeuchi, T | 1 |
| Dobosz, M | 2 |
| Sledziński, Z | 2 |
| Babicki, A | 2 |
| Juszkiewicz, P | 2 |
| Basiński, A | 2 |
| Wajda, Z | 2 |
| Stanek, A | 1 |
| Kawaguchi, S | 1 |
| Kobari, M | 3 |
| Satake, K | 2 |
| Ha, S | 1 |
| Hiura, A | 1 |
| Nishiwaki, H | 2 |
| Haku, A | 1 |
| Umeyama, K | 2 |
| Ono, H | 1 |
| Kondo, T | 1 |
| Shibata, T | 1 |
| Sakai, Y | 1 |
| Kiriyama, S | 1 |
| Sobajima, H | 1 |
| Ino, Y | 1 |
| Kurumi, M | 1 |
| Wisner, JR | 1 |
| Ozawa, S | 1 |
| Renner, IG | 1 |
| Prokopowicz, J | 1 |
| Bodzenta, A | 1 |
| Bielecki, W | 1 |
| Koh, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled, Trial of Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China[NCT02647554] | Phase 4 | 347 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| Fistulotomy as the Primary Cannulation Technique for All Patients Undergoing ERCP: A Randomized, Controlled Trial[NCT04559867] | 538 participants (Anticipated) | Interventional | 2020-09-10 | Recruiting | |||
| RAndomized Clinical Trial in COvid19 Patients to Assess the Efficacy of the Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor NAfamostat (RACONA Study)[NCT04352400] | Phase 2/Phase 3 | 256 participants (Anticipated) | Interventional | 2021-06-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for nafamostat and Acute Edematous Pancreatitis
| Article | Year |
|---|---|
Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review.
Topics: Acute Disease; Antiviral Agents; Benzamidines; COVID-19 Drug Treatment; Fibrinolytic Agents; Guanidi | 2022 |
Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis based on prospective, randomized, and controlled trials.
Topics: Benzamidines; Cholangiopancreatography, Endoscopic Retrograde; Guanidines; Humans; Hyperamylasemia; | 2023 |
Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Cholangiopancreatography, Endoscopic Retrogra | 2014 |
Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Cholangiopancreatography, Endoscopic Retrogra | 2014 |
Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Cholangiopancreatography, Endoscopic Retrogra | 2014 |
Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Cholangiopancreatography, Endoscopic Retrogra | 2014 |
Nafamostat mesilate for prevention of post-ERCP pancreatitis: a meta-analysis of prospective, randomized, controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Cholangiopancreatography, Endoscopic Retrogra | 2015 |
[Treatment of acute pancreatitis with protease inhibitor, H2 receptor antagonist and somatostatin analogue].
Topics: Acute Disease; Aprotinin; Benzamidines; Cimetidine; Drug Administration Schedule; Drug Therapy, Comb | 2004 |
[Continuous regional arterial infusion of protease inhibitor and antibiotic for severe acute pancreatitis].
Topics: Acute Disease; Angiography; Anti-Bacterial Agents; Benzamidines; Clinical Trials as Topic; Guanidine | 2004 |
[Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation].
Topics: Acute Disease; Adult; Anticoagulants; Benzamidines; Disseminated Intravascular Coagulation; Extracor | 2000 |
Targeting complement in therapy.
Topics: Anaphylatoxins; Angioedema; Animals; Animals, Genetically Modified; Anti-Inflammatory Agents; Antibo | 2001 |
10 trials available for nafamostat and Acute Edematous Pancreatitis
| Article | Year |
|---|---|
Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial.
Topics: Administration, Intravenous; Adult; Aged; Benzamidines; Female; Guanidines; Humans; Infusions, Intra | 2020 |
Nafamostat Mesylate is Not Effective in Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis.
Topics: Adult; Aged; Aged, 80 and over; Benzamidines; Cholangiopancreatography, Endoscopic Retrograde; Femal | 2021 |
Randomized controlled trial for efficacy of nafamostat mesilate in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Cholangiopancreatogr | 2015 |
A Randomized Comparative Study of 24- and 6-Hour Infusion of Nafamostat Mesilate for the Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Prospective Randomized Comparison Trial.
Topics: Benzamidines; Cholangiopancreatography, Endoscopic Retrograde; Guanidines; Humans; Pancreatitis; Pro | 2016 |
Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Cholangiopancreatography, Endoscopic Re | 2009 |
The results of severe acute pancreatitis treatment with continuous regional arterial infusion of protease inhibitor and antibiotic: a randomized controlled study.
Topics: Acute Disease; Anti-Bacterial Agents; Benzamidines; Drug Administration Schedule; Drug Therapy, Comb | 2010 |
Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized, double-blind, controlled trial.
Topics: Adult; Aged; Benzamidines; Chi-Square Distribution; Cholangiopancreatography, Endoscopic Retrograde; | 2011 |
Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?
Topics: Acute Disease; Aged; Amylases; Benzamidines; Cholangiopancreatography, Endoscopic Retrograde; Dose-R | 2011 |
[Could nafamostat or gabexate prevent the post endoscopic retrograde cholangiopancreatography pancreatitis?].
Topics: Adult; Aged; Aged, 80 and over; Benzamidines; Cholangiopancreatography, Endoscopic Retrograde; Femal | 2012 |
Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Benzamidines; Drainage; Female; Guanidines; Humans; Imi | 1996 |
46 other studies available for nafamostat and Acute Edematous Pancreatitis
| Article | Year |
|---|---|
Incidence and risk factors for hyperkalaemia in patients treated for COVID-19 with nafamostat mesylate.
Topics: Benzamidines; COVID-19 Drug Treatment; Dexamethasone; Guanidines; Humans; Hyperkalemia; Incidence; P | 2022 |
The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis.
Topics: Benzamidines; Cholangiopancreatography, Endoscopic Retrograde; Guanidines; Humans; Pancreatitis; Ret | 2022 |
Identification of Risk Factors for Phlebitis in Patients Treated with Nafamostat Mesylate.
Topics: Acute Disease; Guanidines; Humans; Pancreatitis; Risk Factors | 2023 |
Nafamostat mesilate prevented caerulein-induced pancreatic injury by targeting HDAC6-mediated NLRP3 inflammasome activation.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Ceruletide; Histone Deacetylase 6; Inflammasomes; | 2023 |
Effectiveness of Plasma Exchange for Acute Pancreatitis Induced by Hypertriglyceridemia During Pregnancy.
Topics: Adult; Anticoagulants; Benzamidines; Disseminated Intravascular Coagulation; Female; Guanidines; Hum | 2016 |
A sudden onset of diabetic ketoacidosis and acute pancreatitis after introduction of mizoribine therapy in a patient with rheumatoid arthritis.
Topics: Acute Disease; Aged; Arthritis, Rheumatoid; Benzamidines; Diabetic Ketoacidosis; Drug Therapy, Combi | 2008 |
Utility of the new Japanese severity score and indications for special therapies in acute pancreatitis.
Topics: Acute Disease; Benzamidines; Enteral Nutrition; Female; Guanidines; Humans; Infusions, Intra-Arteria | 2009 |
Brugada-like electrocardiographic pattern due to hyperkalemia.
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Brugada Syndrome; Electroc | 2009 |
The proteinase/proteinase-activated receptor-2/transient receptor potential vanilloid-1 cascade impacts pancreatic pain in mice.
Topics: Acute Disease; Animals; Benzamidines; Capsaicin; Ceruletide; Disease Models, Animal; Gene Expression | 2010 |
Nafamostat mesilate-induced hepatocellular necrosis in a child with pancreatitis caused by pancreaticobiliary maljunction: drug-induced liver injury.
Topics: Benzamidines; Biopsy; Chemical and Drug Induced Liver Injury; Child, Preschool; Cholangiopancreatogr | 2012 |
Compatibility of carbapenem antibiotics with nafamostat mesilate in arterial infusion therapy for severe acute pancreatitis: stabilities of carbapenem antibiotics.
Topics: Acute Disease; Benzamidines; Carbapenems; Drug Stability; Guanidines; Humans; Infusions, Intra-Arter | 2012 |
[A case with severe acute pancreatitis treated by regional arterial infusion of nafamostat mesilate and imipenem via both celiac artery and superior mesenteric artery].
Topics: Acute Disease; Aged; Benzamidines; Celiac Artery; Cilastatin; Cilastatin, Imipenem Drug Combination; | 2002 |
Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit.
Topics: Acute Disease; Anti-Bacterial Agents; Benzamidines; Drug Therapy, Combination; Female; Guanidines; H | 2004 |
Rat experimental model of continuous regional arterial infusion of protease inhibitor and its effects on severe acute pancreatitis.
Topics: Animals; Benzamidines; Celiac Artery; Disease Models, Animal; Guanidines; Infusions, Intra-Arterial; | 2005 |
Effects of nafamostat mesilate on the prevention of cerulein-induced acute pancreatitis.
Topics: Amylases; Animals; Benzamidines; Ceruletide; Female; Guanidines; Interleukin-6; Lipase; Mice; Mice, | 2008 |
[Pharmacological studies of FUT-175, nafamstat mesilate. II. Effects on experimental acute pancreatitis].
Topics: Acute Disease; Amylases; Animals; Benzamidines; Blood Glucose; Blood Pressure; Dogs; Female; Guanidi | 1984 |
Therapeutic regimens in acute experimental pancreatitis in rats: effects of a protease inhibitor, a beta-agonist, and antibiotics.
Topics: Acute Disease; Adrenergic beta-Agonists; Amylases; Animals; Benzamidines; Diatrizoate Meglumine; Ent | 1995 |
Nafamostat mesilate on the course of acute pancreatitis. Protective effect on peritoneal permeability and relation with supervening pulmonary distress.
Topics: Acute Disease; Animals; Benzamidines; Dextrans; Fluorescein-5-isothiocyanate; Guanidines; Male; Panc | 1994 |
Activation of trypsinogen in experimental models of acute pancreatitis in rats.
Topics: Acute Disease; alpha-Macroglobulins; Animals; Benzamidines; Ceruletide; Disease Models, Animal; Guan | 1995 |
The effect of nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) on multiorgan oxidant-antioxidant balance in acute experimental pancreatitis.
Topics: Acute Disease; Animals; Benzamidines; Gabexate; Guanidines; Lung; Male; Malondialdehyde; Oxidative S | 1994 |
Hyperkalemia due to nafamostat mesylate.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Guanidines; Humans; Hype | 1995 |
[Marked improvement of "severe acute pancreatitis" with continuous administration of protease inhibitor: nafamostat mesilate (Futhan) via intraarterial infusion in a case].
Topics: Acute Disease; Benzamidines; Guanidines; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancr | 1996 |
[A case of pancreatic pleural effusion and ascites treated successfully with conservative measures including octreotide and nafamostat mesilate].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ascites; Benzamidines; Drug Therapy, Combination; Gastroint | 1996 |
[Continuous arterial infusion of protease inhibitor with supplementary therapy for the patients with severe acute pancreatitis--clinical effect of arterial injection of ulinastatin].
Topics: Acute Disease; Adult; Benzamidines; Drug Therapy, Combination; Glycoproteins; Guanidines; Humans; In | 1998 |
Pancreatic phospholipase A2 induces bacterial translocation in rats.
Topics: Acute Disease; Animals; Bacterial Translocation; Benzamidines; Cecum; Guanidines; Injections, Intrap | 1999 |
Therapeutic efficacy of continuous arterial infusion of an antibiotic and a protease inhibitor via the superior mesenteric artery for acute pancreatitis in an animal model.
Topics: Acute Disease; Amylases; Animals; Anti-Bacterial Agents; Bacterial Infections; Bacterial Translocati | 2000 |
Long-term effects of nafamostat and imipenem on experimental acute pancreatitis in rats.
Topics: Acute Disease; Animals; Bacterial Infections; Benzamidines; Colony Count, Microbial; Escherichia col | 2000 |
Protective effect of nafamostat mesilate on cellular and lysosomal fragility of acinar cells in rat cerulein pancreatitis.
Topics: Amylases; Animals; Benzamidines; Cathepsin B; Ceruletide; Guanidines; L-Lactate Dehydrogenase; Lysos | 1992 |
[The cellular and lysosomal fragility of pancreatic acinar cells after ligation of pancreatico-biliary duct in the rat and the protective effects of nafamostat mesilate].
Topics: Acute Disease; Amylases; Animals; Benzamidines; Body Water; Cathepsin B; Disease Models, Animal; Gua | 1992 |
[Treatment of acute pancreatitis].
Topics: Acute Disease; Benzamidines; Disseminated Intravascular Coagulation; Drainage; Gabexate; Glycoprotei | 1992 |
Effect of protease inhibitor FUT-175 on acute hemorrhagic pancreatitis in mice.
Topics: Acute Disease; Amylases; Animals; Benzamidines; Choline; Choline Deficiency; Diet; Ethionine; Female | 1992 |
Comparison of different treatment modalities in experimental pancreatitis in rats.
Topics: Albumins; Animals; Benzamidines; Guanidines; Lactones; Male; Orlistat; Pancreas; Pancreatitis; Perfu | 1992 |
Blood platelet function in canine acute pancreatitis with reference to treatment with Nafamostat mesilate (FUT-175).
Topics: Acute Disease; Animals; Benzamidines; Blood Platelets; Dogs; Guanidines; Male; Pancreatitis; Platele | 1992 |
Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benz | 1992 |
[Antienzyme preparations in the treatment of acute pancreatitis].
Topics: Acute Disease; Adult; Aprotinin; Benzamidines; Cytidine Diphosphate Choline; Disseminated Intravascu | 1990 |
Synthetic antiproteases in acute pancreatitis: an experimental study.
Topics: Acute Disease; Animals; Benzamidines; Dogs; Gabexate; Guanidines; Hemodynamics; Hemorrhage; Pancreat | 1992 |
Beneficial effect of therapeutic infusion of nafamostat mesilate (FUT-175) on hemodynamics in experimental acute pancreatitis.
Topics: Acute Disease; Animals; Benzamidines; Dogs; Guanidines; Hemodynamics; Infusions, Intravenous; Male; | 1991 |
[Effect of continuous arterial infusion of protease inhibitor on experimental acute pancreatitis induced by closed duodenal loop obstruction].
Topics: Acute Disease; Animals; Benzamidines; Dogs; Guanidines; Infusions, Intra-Arterial; Necrosis; Pancrea | 1990 |
Effect of a synthetic protease inhibitor (Fut-175) on coagulation abnormalities during experimental acute pancreatitis in dogs.
Topics: Acute Disease; Animals; Benzamidines; Blood Coagulation Disorders; Blood Coagulation Factors; Blood | 1990 |
Prevention of experimental acute pancreatitis by intraduodenal trypsin inhibitor in rat.
Topics: Acute Disease; Animals; Benzamidines; Duodenum; Guanidines; Injections; Male; Pancreas; Pancreatitis | 1990 |
Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats.
Topics: Acute Disease; alpha-Macroglobulins; Animals; Benzamidines; Guanidines; Male; Pancreas; Pancreatitis | 1986 |
The effects of nafamostat mesilate (FUT-175) on caerulein-induced acute pancreatitis in the rat.
Topics: Acute Disease; Animals; Benzamidines; Ceruletide; Chymotrypsinogen; Guanidines; Male; Organ Size; Pa | 1989 |
Continuous arterial infusion of protease inhibitor for severe acute pancreatitis.
Topics: Acute Disease; Adult; Benzamidines; Female; Guanidines; Humans; Infusions, Intra-Arterial; Male; Mid | 1989 |
Effect of continuous arterial infusion of protease inhibitor on experimental acute pancreatitis.
Topics: Acute Disease; Animals; Benzamidines; Dogs; Guanidines; Infusions, Intra-Arterial; Pancreatitis; Pro | 1989 |
Effect of FUT-175 (nafamstat mesilate) on platelets in canine acute experimental pancreatitis.
Topics: Acute Disease; Animals; Benzamidines; Blood Platelets; Dogs; Guanidines; Pancreatitis; Platelet Aggr | 1988 |
Toxic products in hemorrhagic ascitic fluid generated during experimental acute hemorrhagic pancreatitis in dogs and a treatment which reduces their effect.
Topics: Acute Disease; Animals; Ascitic Fluid; Benzamidines; Disease Models, Animal; Dogs; Female; Guanidine | 1985 |